title: Effects of selective thromboxane synthetase inhibitor OKY-046 on plasma prostaglandins in patients with coronary artery disease during exercise.
authors.forename: M
authors.initials: M
authors.lastname: Shikano
authors.forename: K
authors.initials: K
authors.lastname: Ogawa
authors.forename: T
authors.initials: T
authors.lastname: Ito
authors.forename: L S
authors.initials: LS
authors.lastname: Chen
authors.forename: Y
authors.initials: Y
authors.lastname: Ito
authors.forename: M
authors.initials: M
authors.lastname: Imaizumi
authors.forename: T
authors.initials: T
authors.lastname: Uno
authors.forename: S
authors.initials: S
authors.lastname: Tsutsumi
authors.forename: T
authors.initials: T
authors.lastname: Satake
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000179:Acrylates / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008689:Methacrylates / Q000627:therapeutic use*; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D005082:Physical Exertion; D010974:Platelet Aggregation / Q000187:drug effects; D011453:Prostaglandins / Q000097:blood*; D013929:Thromboxane B2 / Q000097:blood; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
chemical_list: D000179:Acrylates; D008689:Methacrylates; D011453:Prostaglandins; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D010088:Oxidoreductases; D013930:Thromboxane-A Synthase; C034364:ozagrel